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doi:10.1016/j.ejvs.2010.08.011Abstract Objectives: To determine healing and recurrence rates following ultrasound-guided
foam sclerotherapy (UGFS) of superficial venous reflux (SVR) in patients with healed (clinical,
etiologic, anatomic and pathophysiologic (CEAP) classification, C5) and open (C6) chronic
venous ulceration (CVU).
Methods: Between 1 March 2005 and 31 December 2009, 130 consecutive patients (132 limbs,
49 CEAP C5, 83 C6) of median age 70 (interquartile range (IQR) 56e76) years underwent UGFS
as part of their treatment for CVU.
Results: The median (IQR) follow-up time was 16 (12e32) months. One C6 patient moved
abroad 1 week after UGFS and was lost to follow-up. Healing was observed in 67/82 (82%) re-
maining C6 patients at a median (IQR) of 1 (1e2) month following their first UGFS treatment. In
49 limbs originally treated for C5 disease, and in 67 limbs treated for C6 that healed following
UGFS, there were five recurrent ulcers during the follow-up period, giving a 4.9% KaplaneMeier
estimate of recurrence at 2 years. In legs treated for C6 and C5 disease, the median (IQR)
ulcer-free periods were 22 (IQR 9e32) and 14 (IQR 8e36) months, respectively.
Discussion: Healing rates following UGFS for CVU are comparable to those reported after
surgery but recurrence may be lower. UGFS is a safe, clinically effective and, thus, highly
attractive minimally invasive alternative to surgery in patients with C5 and C6 disease.
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Healing and Recurrence Rates Following Ultrasound-guided Foam Sclerotherapy 791Chronic venous ulceration (CVU) affects 1% of the adult Euro-
pean population with 0.1% having an open ulcer at any one
time.1,2 CVU adversely impacts health-related quality of life
(HRQL) and imposes a considerable burden on health-care
resources.3e6 CVU results from the effects upon the dermal
microcirculation of ambulatory venous hypertension (AVH)
which, in turn, results from superficial (SVR) and deep venous
reflux (DVR).7e9 In 2007, the Effect of Surgery and Compression
on Healing and Recurrence (ESCHAR) trial showed that while
compressionplus superficial venoussurgery (SVS) forSVRdidnot
appear to increase healing rates, it did significantly reduce CVU
recurrence rates when compared with compression alone.10e12
Whileminimally invasivemethods such as radiofrequency (RFA)
and endovascular laser ablation (EVLA) and ultrasound-guided
foam sclerotherapy (UGFS) have increasingly come to replace
SVS as the preferred treatment for uncomplicated varicose
veins (C2/3 disease), outcome data on patients with C4e6
disease remains limited.13e21With respect toUGFS for CVU, the
number of patients studied thus far has been very small and the
follow-up short.22e26 The aim of the current study is to report
CVU healing and recurrence rates following UGFS.
Methods
Patients
Ethics approval was obtained for this study and patients gave
informed written consent for their inclusion in this work. This
was a study of consecutive UK National Health Service (NHS)
patients undergoing UGFS as part of their treatment for CVU
(C5/C6disease)between1March2005and31December2009.
In clinic, the venous aetiology of the ulceration was
confirmed by means of history, clinical examination, duplex
ultrasound scanning (DUS) and measurement of anklee-
brachial pressure index (ABPI) in all patients supported by
blood tests, histopathology and other specialist investiga-
tions, as required. All patients with confirmed C5/C6
disease in association with significant (>0.5 s) superficial
truncal reflux on DUS have been offered UGFS in addition to
compression, provided they do not have an ABPI < 0.8 or
post-thrombotic DVR and/or obstruction on DUS.27 In this
study, the diameters of the superficial veins to be treated
were not routinely measured or recorded. This is because
we have found such measurements to be associated with
significant inter- and intra-observer variability, reflecting
both true measurement error and physiological variation.
Furthermore, we do not exclude patients from UGFS on the
basis of superficial veins size alone.
Data have been prospectively gathered and entered into
a computerised database for analysis. While awaiting UGFS,
patients were treated with either a multilayer elastic
bandaging system (usually over a non-adherent dressing) or
with knee-length graduated compression (usually RAL class II
(Reichsausschuss fur Leiferbedingungen)) stockings as
appropriate, dependent on size of ulcer, degree of exudate
and patients’ ability to don and doff stockings.
UGFS treatment
Ourmethods have been described in detail elsewhere.20,21,25
However, briefly, prior to treatment, varices and truncalveins were marked using DUS. Patients were positioned in
a semi-recumbent position for great or anterior accessory
saphenous vein (GSV, AASV) or prone for short saphenous vein
(SSV) treatment. Veins were cannulated with one to four
18G, 20G or 22G cannulae (Optiva 2, Smith’s Medical, Wat-
ford, UK) under DUS using local anaesthetic. Tumescent
anaesthesia was not used. Air (2 ml) and 3% or 1% sodium
tetradecyl sulphate (STS) (0.5 ml) (Fibrovein; STD Phar-
maceuticals, Hereford, UK) were oscillated between two 2-
ml syringes connected by a 5-m filter (B Braun Medical,
Sheffield, UK). Inter-fascial trunks and major tributaries
were treated with 3%, and extrafascial veins usually with 1%
or 0.5% STS foam. Foam was injected in 2-ml aliquots
(maximum 14 ml) and its progress and venous spasm moni-
tored by DUS. There was a minimum interval of 30 s and
patients dorsi- and plantar-flexed their ankles between each
injection. Cannulae were removed and with the limb still in
elevation, a roll of orthopaedic wool (Velbande Johnson and
Johnson Medical, Ascot Berkshire, UK) was applied directly
along the treated veins and retained using Pehahaft cohesive
bandage (Hartmann, Germany). A thigh-length class II
compression stocking (Credelast; Credenhill, Ilkeston, UK)
was applied and left in place for 5e10 days until the patient
was reviewed in clinic. Bandaging was then removed and the
stockingworn until the next follow-up at 1month. In patients
with significant ulcer exudate, to allow dressing changes, the
full-length stocking was cutoff just below the knee and
a multilayer, graduated, elastic bandaging system (usually
worn over a non-adherent dressing) applied up the level of
the tibial tuberosity. Patients were advised to wear below-
knee European (RAL) class II stockings during the day after
ulcer healing. All patients were provided with 24/7 contact
telephone numbers in case of any concerns.
Outcome measures and follow-up
Patients were reviewed at 5e10 days; 1 month, 6 months,
12 months; and then, annually. At follow-up, patients were
asked about side effects including visual disturbance,
headaches and thrombophlebitis. Legs and ulcers were
examined and a DUS was performed to look for deep vein
thrombosis (DVT) and to assess the extent of superficial
occlusion or recanalisation. Superficial venous occlusion of
the treated veins was determined by a lack of compress-
ibility and the absence of any flow. Recanalisation was
defined as the presence of flow in either an antegrade or
retrograde direction in a previously occluded segment.
Patients identified on DUS follow-up surveillance as having
residual, recurrent or new saphenous truncal reflux were
offered further UGFS. Ulcer healing was defined as
complete re-epithelialisation of the leg (for more than 2
weeks), and ulcer recurrence as any loss of skin continuity.
Statistical analysis
Comparisons of continuous non-parametric data were made
by the ManneWhitney-U test and a p value of <0.05 was
considered significant. Ulcer healing and recurrence
following UGFS were estimated using KaplaneMeier survival
analysis. Time to healing was calculated from the date of
first UGFS treatment session for patients treated for open
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the date of healing for patients treated for open ulcers and
from the date of first UGFS session for those treated for
healed ulcers (CEAP C5). Patients who died or were lost to
follow-up were censored. All analyses were carried out
using Statistical Package for Social Sciences (SPSS) Statistics
version 18.0 for Windows.
Results
Between 1 March 2005 and 31 December 2009, 130
consecutive patients (132 limbs, 49 C5 and 83 C6) of median
age 70 (interquartile range (IQR) 56e76) years underwent
UGFS at a median (IQR) of 6 (2e12) weeks after being first
seen in clinic. At referral, 96 limbs had primary SVR, 32 had
recurrent (after previous surgery in the same leg and
saphenous territory) and four had both primary and recur-
rent SVR. DVR was present in 19 limbs. Peripheral pulses
were palpable in 125 limbs. Where pulses were not
palpable, ABPIs were >0.8 in all cases. Three patients had
previous arterial interventions: two popliteal angioplasty
and one femoralepopliteal bypass. There was a history of
DVT in 13 patients; this was multiple in three patients
(Table 1). In 67 C6 legs where the data were prospectively
recorded, the median (IQR) ulcer duration was 8 (3e12)
months and in 40 C6 legs where the data were prospectively
recorded, the median (IQR) ulcer diameter was 3 (1e5) cm.Table 1 Characteristics of treated patients and limbs.
Characteristics All limbs (n Z 132) Total
(%)C5
(n Z 49)
C6
(n Z 83)
Gender
Male 28 37 65 (49)
Female 21 46 67 (51)
Previous DVT 8 5 13 (10)
Pre-treatment duplex findings
Primary SVR 31 65 96 (73)
Recurrent SVR 16 16 32 (24)
Primary and recurrent SVR 2 2 4 (3)
DVR 7 12 19 (14)
Side
Right 21 40 61 (46)
Left 28 43 71 (54)
Refluxing segments on duplex
GSV primary 25 55 80 (54)
GSV recurrent 15 21 36 (24)
SSV primary 8 10 18 (12)
SSV recurrent 4 1 5 (3)
AASV primary 3 4 7 (5)
AASV recurrent 3 0 3 (2)
CEAP 5Z healed ulcer; CEAP 6Z open ulcer; DVTZ deep vein
thrombosis; SVR Z superficial venous reflux; DVR Z deep
venous reflux; GSV Z great saphenous vein; SSV Z short
saphenous vein; AASV Z anterior accessory vein. Recurrent
means at least one previous operation in that saphenous
distribution in that leg.In 95 limbs where the data were collected prospectively,
the median (IQR) volume of foam used was 8 ml (10e12 ml).
One C6 patient left the country 1 week after uneventful
UGFS and was excluded from further analysis.
No immediate, medium and long-term complications
were reported. Specifically, there was no DVT (clinically or
on DUS) or pulmonary embolism (PE), visual disturbance or
any neurological side effects. There were seven unrelated
deaths at 4, 12, 21, 26, 34, 44 and 46 months after treat-
ment; all had been treated for C6 disease. The patient, who
died at 4 months, did so from congestive cardiac failure and
was a 64-year-old male, who received UGFS for left-sided
recurrent GSV reflux in association with C6 disease. No
post-UGFS complications were reported and the ulcer
healed by 1 month after UGFS.
In 120 legs, all SVRs were successfully eradicated
following a single session of UGFS and remained so during
follow-up. 12 limbs underwent a second UGFS session. In
two patients, this was because the first treatment had not
completely eradicated all SVR. One ulcer was already
healed prior to the second treatment and the other healed
within 2 months of the second session. 10 patients were
treated for recurrent (recanalisation) or new (not present
at first UGFS treatment) reflux during follow-up. Of these,
six had been treated for C6 disease (five had healed prior to
the second UGFS treatment and one remained unhealed)
and four patients were treated for C5 disease, which
remained healed at the time of the second UGFS treat-
ment. One limb, originally treated for an open ulcer,
underwent a third UGFS treatment session 3 years after the
second session for recurrent venous reflux.
The median (IQR) follow-up for C6 legs was 16 (12e32)
months. Healing was observed in 67/82 (82%) C6 patients at
a median (IQR) of 1 (1e2) month following their first UGFS
treatment (Fig. 1). The median (IQR) duration of ulcer prior
to treatment in the non-healed and healed groups was 24
(11e48) and 6.5 (5e12) months, respectively (p Z 0.001).
In 49 limbs originally treated for C5 disease and 67 limbs
originally treated for C6 disease, and those healed
following UGFS, 5/116 (4.3%) ulcers recurred at 4.5, 4.5, 5,
24 and 33 months during a median (IQR) follow-up of 15
(12e35) months. In the KaplaneMeier analysis, the esti-
mated cumulative proportion remaining healed at 2 years is
95.1% (Fig. 2).
Of the five recurrent ulcers, four had originally been
treated for C6 and one for C5 disease. Three (all originally
C6) ulcers recurred within 5 months and were associated
with discontinued use of compression stockings. Two had
DVR and one had some recanalisation on duplex. The other
two ulcers recurred at 24 (C5) and 33 (C6) months after
UGFS. Neither patient had DVR, but did have partial
recanalisation. In legs treated for C6 and C5 disease, the
median (IQR) ulcer-free periods were 22 (IQR 9e32) and 14
(IQR 8e36) months, respectively.Discussion
The main finding of this prospective study of 132 limbs
affected by CEAP C5 or C6 disease is that when combined
with compression, eradication of SVR by means of UGFS
leads to an 81% healing rate at 6 months and 5% recurrence
Numbers at risk 
82 14 9 4 3
Figure 1 KaplaneMeier analysis of ulcer healing in 82 limbs
treated with UGFS for C6 disease.
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than that achieved with compression alone (typically
26e28% at 12 months, 40% at 2 years and 56% at 4 years in
the ESCHAR trial) and following SVS combined with
compression (w20% at 2 years and 31% at 4 years in the
ESCHAR trial).10e12,28e36 Patients with CVU are often old
and frail and hence, poor candidates for surgery and
general anaesthesia; making incisions through diseased skin
is also problematic. It seems reasonable, therefore, to
suggest that, where possible, such patients should be
treated by minimally invasive alternatives.37,38 To our
knowledge, there are five published reports on outcomes
following UGFS for patients with CVU, although all theNumbers at risk 
116 66 48 18 
Figure 2 KaplaneMeier analysis of ulcer recurrence 49 limbs
originally treated for C5 disease and 67 limbs treated for C6
that healed after UGFS.studies are small in size and present only short-term
results.25,36,39e41 In our pilot study of 27 patients (28 limbs),
we reported that UGFS combined with compression resul-
ted in a healing rate of 96% at 6 months and that only two
ulcers (7.1%) had recurred at 12 months.25 Cabrera et al.
reported similar outcomes in a retrospective study of 116
patients (151 ulcers). At 6 months, complete healing was
seen in 83% of the patients, with median time to healing of
2.7 months. Seven patients never healed; one patient was
lost to follow-up; and 10 patients (8.6%) had recurred
ulcers; the 24-month recurrence rate was 6.3%.26 Bergan
et al. described their experience in 50 limbs with CEAP C6
disease treated with compression alone (n Z 22),
compression followed by UGFS when compression alone
failed (n Z 13) and UGFS plus compression (n Z 15). At 6
weeks, 10 (46%) limbs had healed in the compression alone
group compared with all the ulcers in the other two
groups.40 In a study of nine patients with 13 CVUs treated
with UGFS, Hertzman reported healing in two ulcers and
improvements in another nine at 2 weeks.41 O’ Hare and
Earnshaw randomised 22 patients to four-layer compression
bandages alone (control) and 18 patients to compression
plus UGFS. At 24 weeks, 17/20 in the control group and 12/
13 patients in the UGFS group had healed.39
In the current study, only 15/82 C6 legs remained
unhealed at the time of analysis. Three had DVR on DUS
prior to UGFS. The mean duration of ulcer prior to UGFS was
significantly longer in the non-healed ulcers. This supports
the findings of several other groups and, once again, shows
how important it is that all patients with leg ulcers are
referred for specialist assessment and treatment as soon as
possible.26,42 The number of recurrent ulcers in the present
study is too small to allow for an analysis of predictive
factor.
At the time most of these patients underwent UGFS, we
were not specifically identifying and treating perforator
disease. We are currently conducting studies in that area.
However, we note (anecdotally at this stage) that perfo-
rators in the vicinity of the ulcer are often occluded
following UGFS.
The majority of the C6 patients were already being
treated with compression in primary care at the time of
referral and yet had failed to heal. After assessment in
clinic, all patients were treated with compression therapy
(graduated elastic bandaging or stockings) while awaiting
UGFS. Without a randomised controlled trial (RCT) of
compression versus compression plus UGFS, it would not be
possible to know what proportion of the benefit observed in
this is due to compression and what proportion is due to
eradication of SVR by means of UGFS. However, given that
the ESCHAR trial and other non-randomised studies have
provided clear evidence of benefit from the surgical or
endovenous eradication of SVR, it is questionable whether
a RCT without an intervention arm would be considered
ethical. Even if it were, we would not be in equipoise and
we doubt whether many (any) of our patients would accept
randomisation once they had been informed of the avail-
able data as part of the consent process.
The question then remains as to whether UGFS is
equally, more or less effective than surgery in the treat-
ment of SVR in association with C5/C6 disease. Once again,
a large RCT would be required. However, given that we and
794 K.H. Pang et al.many other groups have shown UGFS to be associated with
a dramatic reduction in morbidity when compared with
surgery (even in young patients with C2/3 disease), we do
not think it would be appropriate to randomise these
elderly, often frail, patients in such a trial (and we are sure
that the great majority would not accept randomisation).
A trial of foam versus another endovenous technique
(RFA, endovascular laser treatment (EVLT)) would be
possible but we think it is unnecessary. Many of the patients
in this study would have been unsuitable for catheter-based
techniques and most would have required adjuvant tech-
niques (foam, phlebectomy). Among the endovenous
options, UGFS is uniquely versatile and able to eradicate, in
a single session in over 90% of patients, all truncal reflux, as
well as reflux in the local veins that ‘feed’ the ulcer under
the surrounding damaged skin. UGFS is also very inexpen-
sive to deliver and, in terms of cost-effectiveness, offers
the best value for money.
Chronic venous insufficiency manifested by C5 and C6
disease is a chronic relapsing condition that requires life-
long medical care (compression), intervention to eradicate
SVR and regular surveillance (with DUS) to allow re-treat-
ment of recurrent or new reflux.
The surgical paradigm that the treatment of C5/6
disease comprises a single ‘high tie and stripping’ operation
(often delayed until the ulcer has healed) followed by
compression stockings and discharge from follow-up is no
longer appropriate. Rather, on the basis of present and
other published data, we strongly believe that it is in our
patients’ best interests to eradicate all SVR by means of
UGFS as soon as possible after the ulcer appears and then
offer further UGFS, which, unlike ‘redo’ surgery is simple,
safe and effective, as and when recurrent or new SVR
develops.43
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